Is BPC-157 Legal Again? FDA Category 2 Removal Explained (April 2026) | Peptadex

The Short Answer

BPC-157 is not fully legal to compound yet — but its path to legal compounding pharmacy access has opened significantly. Effective April 22, 2026, BPC-157 is being removed from the FDA's Category 2 list. It is then scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026. Only after a positive PCAC vote and addition to the 503A bulk drug substances list will licensed compounding pharmacies be legally authorized to prepare BPC-157 with a valid physician prescription.

Key Takeaways

• Effective April 22, 2026: BPC-157 removed from FDA Category 2 (which previously restricted its compounding)
• July 23, 2026: PCAC advisory panel reviews BPC-157 alongside KPV, TB-500, and MOTS-c
• Removal from Category 2 does NOT equal FDA approval or immediate legal compounding
• The regulatory shift was announced February 27, 2026 by RFK Jr. / HHS
• BPC-157 still has only 3 published human studies as of March 2026

What Is the FDA Category 2 List?

The FDA's Category 2 list designates bulk drug substances that present potential safety risks and therefore cannot be used by compounding pharmacies. Being on Category 2 effectively blocked licensed pharmacies from preparing BPC-157 for patients, even with a doctor's prescription, since 2020.

Before 2020, BPC-157 existed in a regulatory gray zone where compounding pharmacies could prepare it. When the FDA added it to Category 2, that access was formally removed.

The February 27, 2026 Announcement

On February 27, 2026, Secretary of Health and Human Services Robert F. Kennedy Jr. announced that 14 of 19 peptides on the Category 2 list would be moved to Category 1 (the pathway for lawful compounding) or removed from the list entirely. The announcement cited access concerns and the peptide community's longstanding interest in legal compounding options.

Critically, this was an announcement of intent — not an immediate regulatory change. The FDA then published the formal timeline, with removal from Category 2 taking effect April 22, 2026, and the advisory panel scheduled for late July.

The April 22, 2026 Effective Date

As of April 22, 2026, BPC-157 is no longer on the Category 2 list. This removes the specific prohibition that blocked compounding pharmacies from preparing it. However, this intermediate step is often misunderstood as equivalent to legalization.

For BPC-157 to be legally compoundable by a licensed 503A pharmacy, it must be affirmatively listed on the bulk drug substances list. That requires a positive PCAC recommendation followed by FDA administrative action. This process is expected to take several months after the July 23 panel.

The July 23 PCAC Panel

The Pharmacy Compounding Advisory Committee will convene July 23, 2026 to review BPC-157 alongside three other peptides: KPV, TB-500, and MOTS-c. The panel will consider the existing clinical evidence, safety data, and whether there is sufficient therapeutic rationale to allow compounding.

Given that BPC-157 has only 3 published human studies as of March 2026 (all small pilot studies), the panel will be working with a limited clinical evidence base. Two systematic reviews published in early 2026 cover the musculoskeletal animal literature and provide the strongest current case for the compound's potential utility.

What This Means for Patients and Providers

The regulatory timeline has practical implications:

• Before July 23, 2026: BPC-157 is neither prohibited nor affirmatively permitted for compounding — it exists in a transitional state. Most reputable compounding pharmacies will wait for positive PCAC action before stocking it.
• After positive PCAC vote (estimated August–October 2026): Licensed 503A compounding pharmacies with physician prescriptions could begin preparing BPC-157 legally.
• Gray market sources: Research peptide vendors operating outside the pharmaceutical compounding system are a separate legal category. These are not compounding pharmacies and their products are not subject to USP standards or pharmacy oversight.

How Does BPC-157's Legal Status Compare to TB-500?

TB-500 is on the same July 23 PCAC agenda as BPC-157. The two peptides are frequently studied and discussed together in recovery research. Compare their profiles side-by-side using our comparison tool.

The Evidence Base for BPC-157 in 2026

Two systematic reviews published in early 2026 examined BPC-157's musculoskeletal evidence:

• A systematic review in PMC covering BPC-157 in orthopaedic sports medicine found preclinical evidence for tendon, ligament, and bone healing effects in animal models, while noting the absence of large human trials.
• A narrative review titled "Regeneration or Risk?" provided balanced clinical context, emphasizing the need for controlled human studies before clinical recommendations can be made.

Both reviews conclude that while the preclinical signal is promising, the clinical evidence base is insufficient for formal recommendation as of 2026.

What to Watch

The July 23 PCAC meeting will be a pivotal event for the peptide community. A positive vote would put BPC-157 on the clearest path to legal compounding access it has had in years. A negative vote would likely delay access further and could impact how regulators approach the broader Category 2 reclassification initiative.

Disclaimer: This article is for educational and informational purposes only. Nothing herein constitutes legal or medical advice. Regulatory status of compounds can change rapidly. Consult a qualified healthcare professional and confirm current regulatory status before making any decisions. Always follow applicable laws in your jurisdiction.